Mood Disorders News

SAN ANTONIO — Study data from the National Pregnancy Registry for Atypical Antipsychotics indicate it is unlikely for second-generation antipsychotics to raise risk of major malformations in pregnancy beyond the 10-fold increase found in the general population, said a study co-author here at the U.S. Psychiatric and Mental Health Congress.

SAN ANTONIO — There is ample evidence in modern literature to dispel the myth that there is a placebo response and that the largest incremental response is seen early in treatment, said Mark Zimmerman, MD, of Brown Medical School, Providence, R.I.

SAN ANTONIO — Marlene P. Freeman, MD, of Harvard Medical School and Massachusetts General Hospital, reviewed evidence for pharmacological and non-pharmacological treatments for premenstrual dysphoric disorder and related conditions in a session here at U.S. Psychiatric and Mental Health Congress.

SAN ANTONIO — Pharmacologic treatment should be paired with ‘wise’ non-pharmacologic interventions to improve patient care, said a U.S. Psychiatric and Mental Health Congress co-chair.

SAN ANTONIO — Pilot data from an ongoing clinical trial on a repurposed GLP-1 receptor antagonist has been found to recalibrate the circuits subserving cognition in mood disorders, according a researcher who presented here at U.S. Psychiatric and Mental Health Congress.

SAN ANTONIO — An interactive keynote session here at the U.S. Psychiatric and Mental Health Congress used group sing-a-long to illustrate the power of music to overcome fear and improve mental health.

Findings from a systematic review and meta-analysis indicated efficacy of anti-cytokine therapy for depressive symptoms, suggesting potential utility of these drugs for depression and related disorders.

Average placebo response rates in antidepressant trials have been stable for more than 25 years, according to recent findings.

The U.S. Psychiatric & Mental Health Congress will begin Friday, October 21 and conclude Monday, October 24.

Exposure to selective serotonin reuptake inhibitors in utero may increase risk for speech and language disorders, according to recent findings.